Navigation Links
Researcher tests drug's impact on neurological disease affecting women
Date:6/7/2011

EAST LANSING, Mich. A rare but increasingly more common disease striking overweight, younger women is the focus of a clinical trial at Michigan State University, where an osteopathic physician is testing the effectiveness of a certain drug against a potentially blindness-causing ailment.

Idiopathic intracranial hypertension, known as IIH or pseudo-tumor cerebri, is a neurological disease resulting in increased pressure around the brain, specifically in the absence of a tumor. Symptoms include severe headaches, nausea and double vision, and if left untreated, IIH can lead to vision loss and blindness.

Eric Eggenberger, professor and associate chairperson in MSU's Department of Neurology and Ophthalmology, is leading a clinical trial to test the ability of a commonly used diuretic known as acetazolamide in reducing or reversing vision loss in patients with IIH. Diuretics are drugs that increase the rate of urination.

"While weight loss is always recommended for women suffering from IIH, many other treatments are used to battle the disease by decreasing pressure around the brain," said Eggenberger, a member of MSU's HealthTeam.

"The problem is, none of these strategies have been verified by clinical trials, and there is no compelling evidence on which treatments work best and why."

In addition, he said, more evidence is needed on the potential side effects of drugs such as acetazolamide.

Though IIH is rather rare, affecting only 22 out of every 100,000 Americans, its incidence rate is rising in parallel with the obesity epidemic sweeping the nation. The cause of the endocrine-based disease is not known, but it usually affects women of child-bearing age who are overweight or obese. It is rare in post-menopausal women and men of all ages.

The clinical trial run by Eggenberger at MSU has three main goals: establish evidence-based treatment strategies to restore and protect vision, follow patients for up to four years to observe long-term treatment outcomes and help determine the cause of IIH.

All patients in the trial will receive Web- and phone-based diet information to help subjects lose weight. The study also will randomly assign patients to one of two groups: those receiving acetazolamide and those receiving a placebo. Patients will be monitored for six months to test the impact of the drug.

Subjects also will undergo genetic screening, specifically looking at vitamin A and genes that may be risk factors for IIH. That analysis could help researchers with the frustrating task of pinpointing what causes the disease, Eggenberger said.


'/>"/>

Contact: Jason Cody
codyja@msu.edu
517-432-0924
Michigan State University
Source:Eurekalert  

Related medicine news :

1. A decade dedicated to breast cancer care advocacy garners ASCO Award for researcher
2. Researchers discover biochemical weakness of malaria parasite -- vaccine to be developed
3. Researchers find that inhibiting microRNAs may help prevent degenerative eye disorders
4. CWRU researcher studies ways to help teens overcome fears and stigmas of mental illness
5. Calorie-burning brown fat is a potential obesity treatment, researchers say
6. City of Hope researchers to present rectal cancer, palliative care, benchmarking studies at ASCO
7. U of Alberta researchers hoping to stop heart disease in cancer patients before it starts
8. U of A researchers hope to stop heart
9. UofL researchers uncover mechanism in saliva production
10. UF researchers suggest cholera vaccination strategies for Zimbabwe
11. Researchers characterize epigenetic fingerprint of 1,628 people
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Researcher tests drug's impact on neurological disease affecting women
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned by ... to enhance the health of felines. The formula is all-natural and is made from ... the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract ...
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016 ... announced the addition of the " Global Markets ... This report focuses ... an updated review, including its applications in various applications. ... market, which includes three main industries: pharmaceutical and biotechnology, ...
(Date:6/24/2016)... , June 24, 2016 Research ... World Market for Companion Diagnostic Tests" report to their ... Market for Companion Diagnostics The World Market ... and personalized medicine diagnostics. Market analysis in the report includes ... Test Market (In Vitro Diagnostic Kits) by Region (N. America, ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced today ... its e-clinical software solution of choice.  This latest ... possible value to their clients by offering a ... preferred relationship establishes nowEDC as the EDC platform ... MedSource,s full-service clients.  "nowEDC has long been a ...
Breaking Medicine Technology: